U.S. markets open in 6 hours 9 minutes
S&P Futures
4,127.50+1.00(+0.02%)Dow Futures
33,724.00+21.00(+0.06%)Nasdaq Futures
13,762.75-31.50(-0.23%)
Coherus BioSciences, Inc. (CHRS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.27+0.13 (+0.92%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 14.14 |
| Open | 14.12 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 14.01 - 14.57 |
| 52 Week Range | 13.53 - 22.22 |
| Volume | 959,931 |
| Avg. Volume | 1,344,365 |
| Market Cap | 1.043B |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | 8.79 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
26% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Simply Wall St.
I Ran A Stock Scan For Earnings Growth And Coherus BioSciences (NASDAQ:CHRS) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
- Motley Fool
3 Undervalued Biotechs Worth Adding to Your Watch List
If you're like me, your investment watch list is overflowing with dozens of stocks and price alerts. Let's examine three biotechs trading at lower than average valuations and consider whether they might be worth putting on your watch list. Supernus Pharmaceuticals (NASDAQ: SUPN) makes drugs that treat disorders of the central nervous system, including epilepsy and Parkinson's disease.
- Motley Fool
Coherus BioSciences Inc (CHRS) Q4 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter and Full Year 2020 Coherus BioSciences Conference Call. Today's call includes forward-looking statements regarding Coherus' current expectations.
© 2021 Verizon Media. All rights reserved.
